The MASTER Study (MAmmary Cancer STatin ER Positive Study)

PHASE3RecruitingINTERVENTIONAL
Enrollment

3,360

Participants

Timeline

Start Date

January 4, 2021

Primary Completion Date

January 1, 2025

Study Completion Date

January 1, 2035

Conditions
Breast Cancer FemaleEstrogen Receptor Positive Tumor
Interventions
DRUG

Atorvastatin 80 Mg Oral Tablet

Atorvastatin 80 mg per day for 2 years

DRUG

Placebo oral tablet

Placebo 1 tablet per day for 2 years

Trial Locations (1)

Unknown

RECRUITING

Aarhus University Hospitak, Aarhus

All Listed Sponsors
collaborator

Rigshospitalet, Denmark

OTHER

collaborator

Hospital of Southern Jutland

OTHER

collaborator

University of Copenhagen

OTHER

collaborator

Bornholms Hospital

UNKNOWN

collaborator

Naestved Hospital

OTHER

collaborator

Vejle Hospital

OTHER

collaborator

Odense University Hospital

OTHER

collaborator

Nordsjaellands Hospital

OTHER

collaborator

Aalborg University Hospital

OTHER

collaborator

Herning Hospital

OTHER

lead

Aarhus University Hospital

OTHER